Inventor · disambiguated record
Michael A. Sandoval
Also filed as: SANDOVAL MICHAEL · SANDOVAL MICHAEL A
6 granted patents·11 pending applications·27 citations·filing 2012–2024
80Inventor score
Top patents by PatentIndex Score
17 records- 0193US9649364B2Methods for producing stable therapeutic formulations in aprotic polar solventsXERIS PHARMACEUTICALS INC·Filed 2016·Granted May 16, 2017·12 cites·16 claims
- 0291US10485850B2Methods for producing stable therapeutic formulations in aprotic polar solventsXERIS PHARMACEUTICALS INC·Filed 2017·Granted Nov 26, 2019·8 cites·12 claims
- 0389US11020403B2Precipitation resistant small molecule drug formulationsXERIS PHARMACEUTICALS INC·Filed 2018·Granted Jun 1, 2021·4 cites·22 claims
- 0486US2024207365A1Methods for producing stable therapeutic formulations in aprotic polar solventsXERIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0586US2024342249A1Methods for producing stable therapeutic formulations in aprotic polar solventsXERIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0683US11260033B2Compositions for the delivery of therapeutic agents and methods of use and making thereofDISRUPTION LABS INC·Filed 2021·Granted Mar 1, 2022·2 cites·15 claims
- 0783US2024041984A1Methods for producing stable therapeutic formulations in aprotic polar solventsXERIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0876US11590205B2Methods for producing stable therapeutic glucagon formulations in aprotic polar solventsXERIS PHARMACEUTICALS INC·Filed 2016·Granted Feb 28, 2023·1 cites·8 claims
- 0967US2020215162A1Methods for Producing Stable Therapeutic Formulations in Aprotic Polar SolventsXERIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1066US11833157B2Precipitation resistant small molecule drug formulationsXERIS PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·0 cites·25 claims
- 1161US2022241217A1Compositions for the delivery of therapeutic agents and methods of use and making thereofDISRUPTION LABS INC·Filed 2022·Application pending·0 cites
- 1260US2021290562A1Compositions for the delivery of therapeutic agents and methods of use and making thereofDISRUPTION LABS INC·Filed 2019·Application pending·0 cites
- 1350US2024374519A1Compositions for supplementing products with therapeutic agents and methods of use thereofDISRUPTION LABS INC·Filed 2022·Application pending·0 cites
- 1446US2023233466A1Compositions for supplementing products with therapeutic agents and methods of use thereofDISRUPTION LABS INC·Filed 2021·Application pending·0 cites
- 1546US2023210771A1Compositions for the delivery of therapeutic agents and methods of use and making thereofDISRUPTION LABS INC·Filed 2021·Application pending·0 cites
- 1638US2019083578A1Use of low dose glucagonXERIS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1738US2013131008A1Lipophilic monophosphorylated derivatives and nanoparticlesUNIV TEXAS·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →